ImmunityBio, Inc. (FRA:26CA)
Germany · Delayed Price · Currency is EUR 5.20
+0.29 (5.84%)
At close: Jan 30, 2026
ImmunityBio Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -348.62 | -413.56 | -583.2 | -416.57 | -346.79 | -221.85 |
Depreciation & Amortization | 15.8 | 17.55 | 18.51 | 18.26 | 14.24 | 12.74 |
Other Amortization | 5.01 | 22.59 | 42.4 | 16.28 | 0.06 | - |
Asset Writedown & Restructuring Costs | - | - | 0.89 | 2.01 | - | 10.66 |
Loss (Gain) From Sale of Investments | -0.95 | -0.86 | 1.45 | 5.51 | 5.02 | -0.68 |
Stock-Based Compensation | 37.1 | 34.43 | 49.16 | 40.18 | 57.18 | 2.19 |
Other Operating Activities | 22.72 | -31.97 | 100.05 | 4.82 | 14.98 | 8.86 |
Change in Accounts Receivable | -27.84 | -2.36 | - | - | - | - |
Change in Inventory | -4.75 | -8.27 | - | - | - | - |
Change in Accounts Payable | -4.38 | -3.17 | -6.48 | 8 | -3.72 | 2.57 |
Change in Other Net Operating Assets | -13.79 | -5.62 | 10.45 | -16 | -15.4 | 13.79 |
Operating Cash Flow | -319.7 | -391.24 | -366.76 | -337.51 | -274.42 | -171.72 |
Capital Expenditures | -5.05 | -6.89 | -30.58 | -78.16 | -33.56 | -1.67 |
Sale of Property, Plant & Equipment | - | - | - | - | 20.5 | - |
Sale (Purchase) of Intangibles | -0.03 | - | - | -21.23 | - | - |
Investment in Securities | -178.45 | -5.36 | 0.11 | 126.69 | -71.82 | -18.14 |
Investing Cash Flow | -183.54 | -12.25 | -30.47 | 27.3 | -84.89 | -19.81 |
Long-Term Debt Issued | - | 96.96 | 451.46 | 174.13 | 338.5 | 63.7 |
Long-Term Debt Repaid | - | -0.06 | -0.08 | -0.06 | - | - |
Net Debt Issued (Repaid) | -0.02 | 96.89 | 451.39 | 174.07 | 338.5 | 63.7 |
Issuance of Common Stock | 454.77 | 190.2 | 110.4 | 60.5 | 169.99 | 87.48 |
Repurchase of Common Stock | -2.48 | -5.47 | -3.44 | -0.62 | -4.06 | -0.5 |
Other Financing Activities | - | - | - | -0.34 | 1.02 | - |
Financing Cash Flow | 452.28 | 281.63 | 558.34 | 233.61 | 505.44 | 150.68 |
Foreign Exchange Rate Adjustments | 0 | -0.02 | -0.29 | 0.28 | 0.05 | -0.03 |
Net Cash Flow | -50.96 | -121.88 | 160.82 | -76.32 | 146.19 | -40.89 |
Free Cash Flow | -324.76 | -398.12 | -397.34 | -415.67 | -307.98 | -173.39 |
Free Cash Flow Margin | -393.38% | -2700.06% | -63881.19% | -173196.25% | -32974.52% | -28660.00% |
Free Cash Flow Per Share | -0.38 | -0.57 | -0.78 | -1.04 | -0.79 | -0.46 |
Cash Interest Paid | 73.6 | 92.32 | 77.19 | 35.44 | 2.11 | 0.04 |
Cash Income Tax Paid | - | 0.02 | 0.01 | 0 | 0.01 | 0.01 |
Levered Free Cash Flow | -230.46 | -256.31 | -234.66 | -299.03 | -170.3 | -94.55 |
Unlevered Free Cash Flow | -158.65 | -182.44 | -196.31 | -275.62 | -161.08 | -88.88 |
Change in Working Capital | -50.76 | -19.42 | 3.98 | -8 | -19.11 | 16.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.